Quick Links
12345

11. Yao, X., et al; InVitro Antiviral Activity and Projection of Optimized Dosing Design ofHydroxychloroquine for the Treatment of Severe Acute Respiratory SyndromeCoronavirus 2 (SARS-CoV-2), March 9 2020, Clinical Infectious Diseases, ciaa237,https://doi.org/10.1093/cid/ciaa237

2 Rosenberg ES., et al;Association of Treatment With Hydroxychloroquine or Azithromycin WithIn-Hospital Mortality in Patients With COVID-19 in New York State JAMA. Published online May 11,2020. doi:10.1001/jama.2020.8630

3Tett SE., et al;Bioavailability of hydroxychloroquine tablets in healthy volunteers. Br J ClinPharmacol. 1989l27 (6) 771-779

4Huang,X., et al; The Role of Macrophages in the Pathogenesis of ALI/ARDS. MediatorsInflamm. (2018): 1264913.

5WorkingerJ., et al; Systemically Administered Plant Recombinant Holo-IntrinsicFactor Targets the Liver and is not Affected by Endogenous B12 levels. Scientific Reports,vol 9, Article number: 12269 (2019).

© All Rights Reserved Xeragenx LLC 0000
(833) 949-9499 | 100 North Point Center East, Suite 125, Alpharetta, GA, 30022
‍Design & Development by Circullar.com

Xeragenx LLC is a biotechnology company specializing in the development, and supply of plant-derived recombinant human Intrinsic Factor (rh-IF) for multiple applications, including use in foods, beverages and dietary supplements.  All information on this website is provided for informational and educational purposes only, and is intended solely as a business-to-business (B2B) communication. This information is not intended for use by consumers and should not be construed as medical advice.

These statements have not been evaluated by the Food and Drug Administration. rh-IF is not intended to diagnose, treat, cure, or prevent any disease.